Immunofluorescence Assay Market 2019 | Key Players are Thermo Fisher, Inova Diagnostics, Bio-Rad, Abcam , PerkinELmer, Danaher
The Report “Immunofluorescence Assay Market by Product (Reagent, Primary & Secondary Antibody, Kit, Imaging Equipment, Immunofluorescence Microscopy), Type (Direct, Indirect), Disease (Cancer, Cardiovascular, Infectious Disease) & End User - Global Forecast to 2023”
The immunofluorescence assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%.
The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market.
Immunofluorescence assay is a powerful technique used to analyze the distribution of glycans, proteins, and small biological and non-biological molecules (cells and tissues) using antibodies conjugated with a fluorescent dye, known as fluorophore, which can be visualized using a fluorescence microscope or imaging systems.
Download a FREE Pdf Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571
Research Methodology
Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of other dependent submarkets. Various secondary sources such as directories, industry journals, databases such as D&B Hoovers, Bloomberg Business, and Factiva, and annual reports of the companies have been used to identify and collect information useful for the study of this market.
Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this immunofluorescence assay industry.
Key Players
The prominent players in the global immunofluorescence assay market are Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US). Read More
The immunofluorescence assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%.
The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market.
Immunofluorescence assay is a powerful technique used to analyze the distribution of glycans, proteins, and small biological and non-biological molecules (cells and tissues) using antibodies conjugated with a fluorescent dye, known as fluorophore, which can be visualized using a fluorescence microscope or imaging systems.
Download a FREE Pdf Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571
Research Methodology
Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of other dependent submarkets. Various secondary sources such as directories, industry journals, databases such as D&B Hoovers, Bloomberg Business, and Factiva, and annual reports of the companies have been used to identify and collect information useful for the study of this market.
Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this immunofluorescence assay industry.
Key Players
The prominent players in the global immunofluorescence assay market are Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US). Read More
Comments
Post a Comment